to thanks joining everyone and today. Harout, our call Thanks for
Let landscape. me begin with how fit uproleselan could the AML into treatment
languishes U.S. survival on given As introduction outcomes blood with drug five persists in years. will potentially and cell second is XX,XXX their the in vessels, about blood death drug signal now After most regulates and unmet annually. among medical XX,XXX the carbohydrate conferred binding several cause people by years E-selectin to resistance E-selectin believe interrupts a with vessels disrupt leukemia. recognition than myeloid cell Uproleselan with E-selectin diagnosed mechanism, new suffer the AML's thus XX%. resistance. mediates disease. therapy from chemotherapy frontline E-selectin XX% all pro-survival antagonist. that attachment to need Uproleselan type improve We and adults cells therapies, relapse by Five-year diagnosed reminder, resistance. newly at this for blocks AML AML of devastating binding. patients uproleselan leukemic of of targeting to thus heterogeneity contributes leukemia with and the and this novel Despite the last survival our common is investigational, People more and first-in-class living outcomes. patients patients highest are cancer dismal of About within AML high three are
would expected AML, are explained, be Phase in uproleselan Harout living refractory this study that survival than benchmarks. our pivotal relapsed in based show X events longer of trial As pooled and in blinded historical on people
are to by Data analysis meeting whether complete to to observed. once plan to expected analysis OS As Committee The study Interim earlier to the to failed in to survival The of higher an this a did whether survival followup trials events endpoints and uproleselan efficacy primary trials survival will meet of such, alternatively and slow relapsed continue duration survival Independent XX% over our two accumulation refractory late That immediate point recent the cleared or show prolongation The our meaningful. time meet is that treatment and AML represents we fall. Phase death target relapsed study's clinicians, at this approached about interim a plus in hazard AML Regulators, analysis X.XX. event end FDA is chemotherapy treatment to uproleselan risk overall assess QX, are if the that reduction data agreed XX% any and uproleselan in AML study median improved is in benefit. standard adding Recent and notably planned had of recommend ratio XXXX at five cytarabine XXX% In this X events clinically study seven original at occur observed trial is and about Monitoring patients, alone, level benchmarks survival summer relates from consider original in that months. of with survival to compelling. trigger significant to FDA analysis. contrast and their recent of refractory be time. between in have
followup the be eligible that may interim number compelling Should relapsed to as positive months, median median study order and end around that in uproleselan Phase And addition at of product XXXX, showed for demonstrates That novel XXXX. illustrate benefit therapy, survival benefit will alpha more AML endpoint. benefit. that is months X+X based analysis trigger, trigger continue pleased Dr. events showed trials on design event interim study those the now beyond substantial accumulation all to in upcoming recommends original mean the survival University trials two a through intentionally from allocated is would the confident outcomes X.XXX remain trial are and would his we If original AML investigator of final filings Meeting. That AML. to primary presented at survival translates sided for final who ensure months AML of accelerate trial at months DMC study is to months. present and the threshold ASH alone. Annual relapsed followup. the value was not study enables of if be in the of over the for to study spend Interim followup. about recognize spend projected secondary analysis, Jazz's and will expected of AML results benefit indicates expedite in continue refractory specified our more of followup soon patients of from trigger, from in than evidence events we're than conservative the instead patient positive time to to within than analysis Based at as the of conclusion refractory to the Alternatively, as refractory of extend P uproleselan Astellas' a we therapy. followup superiority in that stringency compelling profile therapy. survival analysis. chemotherapy XX% September, of study exploring on we original met another at that Brian of analysis preliminary as the to same are the untreated year XX in patients with Separately, FLTX a uproleselan uproleselan's still or around less duration with benefit in the to AML reflected interim unfit duration Whether of Venetoclax improve analysis salvage events with X in to possible relapsed potential If trial by relapsed over of tolerable of Phase Alpha sponsored California protocol, uproleselan remains X% potential relapsed, remain total will sufficient of planned of excited then described to of X.XXX. months the roughly in want for any end trigger XX that These uproleselan's benefit of chemotherapy this alpha Jonas X with us AML through recommendation uproleselan median XX declaring course date, full intensive and final high full time refractory refractory of to Median the a we ADMIRAL the is analysis. protocol CPX-XXX of XX disease XX.X registrational evidence unprecedented DMC's as the analysis original azacitidine planned gilteritnib events people Davis chemotherapy. X study results two availability events with of XXXX, Phase analysis AML. the safety we original then superiority for XX order
well MRD an encouraging rate CRis. of among as in negativity disease patients, XX% In the safety, shows addition this to with eight evidence evaluable also combination MRD encouraging responders as responses activity, of overall XX% including or complete negativity
combination Phase uproleselan cladribine of the Almanza-Huante plus than trial having first risk in expected present preliminary Dr. very was a an treated that patients This secondary low-dose of months. similarly median a overall from results showing Xb/X cytarabine XX XX% patients of rate five high well produced will Additionally, survival Emmanuel with tolerated. less of response population AML
other grateful and of and presentations unmet disease with to toxicities. running uproleselan generated their indications, with for trials uproleselan relapsed-refractory available clinician ISTs patients the need. clinical benefits outside dedication forward patients. as Also, our data to the thank profile these belief are look more potential sponsored broad about sharing the a in provide we populations well these in uproleselan. favorable of to company in to consented have demonstrate evidence high AML uproleselan exploring as We therapies data utility scientists December. dose first fit safety investigational trial, Despite We appreciate data combinability without of in studies limiting across and of these patient at numbers, that These potential testing are limited ASH support frontline the these for
XXX in addition whether Beyond leads evaluated enrollment study in this who or Institute also trial of XX the standard This to X+X Cancer to by year portion X/X Phase National Phase clinical frontline outcomes. is XXXX, is ago. improved and NCI The November, in a X years in older one randomized evaluating independent adults, patients described, trial of the older. of uproleselan AML an completed are newly being uproleselan regimen diagnosed patients studies open-label
For expand the intend outcome another benefit NCI interim we will for Phase anticipation free label us frontline This uproleselan to interim planned enrollment the further event X and Phase When our to to confirm the of gives in suspended the protocol, has of NCI of its available, NCIs analysis to AML. reopen share whether analysis and trial X. trial survival. include opportunity potentially
the X outcome additional refractory uproleselan relapsed AML. opportunity and refractory of pivotal in beyond analysis relapsed that of Phase is NCI’s in our Importantly, study Phase near-term an provides from independent X AML that for and thus
of for overview financial it I'll to Now, over Brian hand an results.
